Cefotetan for E. coli bloodstream infections
Part of Infections clinical trials.
This study tests whether a simpler antibiotic, cefotetan, works as well as the usual treatment for E. coli bloodstream infections. It may offer an effective option with fewer side effects for some patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an E. coli bloodstream infection confirmed by a lab test.
- Your infection must be treatable with cefotetan and the standard comparison antibiotic.
- You must not be allergic to cefotetan or the comparison antibiotic.
- You must not have had a serious E. coli bloodstream infection in the past 30 days.
- You must not be pregnant or breastfeeding.
- You must not have a weakened immune system or severe illness requiring intensive care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
This trial tests a combination of two antibiotics (cefepime and enmetazobactam) to treat complicated urinary tract infections that have spread to the blood. It aims to see if this new combination works better than other antibiotics and is safe for patients.
This study looks at whether using two or more antibiotics together works better than one alone for a specific type of blood infection caused by Enterococcus faecalis bacteria. The goal is to find the safest and most effective way to treat this infection and improve outcomes for patients.
This trial looks at how well certain penicillin-type antibiotics work for treating a bloodstream infection caused by a bacterium called Enterococcus faecalis. It may help doctors know which treatment is best for patients with this infection.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
Hear when a new E Coli Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.